Therapy Areas: Diabetes
UPMC Health Plan signs value-based agreement with Boehringer Ingelheim for Jardiance (empagliflozin) for type 2 diabetes
28 September 2018 -

Health care insurer UPMC Health Plan revealed on Thursday the launch of a value-based contract with Boehringer Ingelheim for the oral type 2 diabetes medicine, Jardiance (empagliflozin).

Effective 01 January 2019, the objective of the contract is to align the incentives of the manufacturer, Boehringer Ingelheim, with the UPMC Health Plan, and will link reimbursement of the drug to costs associated with clinical outcomes in the real-world population.

In a first-of-its-kind contract, the reimbursement for Jardiance will be linked to total costs of care for all people with diabetes treated.

Jardiance (empagliflozin), an oral type 2 diabetes medicine indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Jardiance is a product in the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance portfolio.

Currently, Jardiance is the only SGLT2 inhibitor recommended in the ADA 2018 Standards of Medical Care in Diabetes for reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, the number one cause of death for people with diabetes.

The development of the value-based contract was reportedly led by the Center for Value-Based Pharmacy Initiatives, the UPMC Insurance Services Division's non-for-profit research group and benefited from engagement of leaders across UMPC, an integrated payor and provider.

Login
Username:

Password: